N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Sponsor: Boehringer Ingelheim • ClinicalTrials.gov ID: NCT07201922

Registry updated: 2026-09-30
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis. Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo. Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months. Doctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.

Interventions

  • Nerandomilast (Drug)
    Nerandomilast
  • Placebo (Drug)
    Placebo

Eligibility criteria

Inclusion Criteria: * Individuals ≥40 years of age at the time of first signed informed consent at Visit 1a * Participants must have at least 1 first-degree relative (biological parent, sibling, or child) with confirmed pulmonary fibrosis (idiopathic pulmonary fibrosis \[IPF\], idiopathic nonspecific interstitial pneumonia \[NSIP\], and/or pulmonary fibrosis due to known genetic cause \[e.g. short telomere syndrome, mucin 5B (MUC5B) mutation, surfactant protein mutations\]) * High resolution computed tomography (HRCT) scan with evidence of interstitial lung abnormalities involving at least 5% of a single lung zone or interstitial lung disease (ILD), based on central evaluation * Forced vital capacity (FVC) ≥80% of predicted normal at Visit 1b * Diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin ≥70% of predicted normal at Visit 1b Further inclusion criteria apply. Exclusion Criteria: * Prior known pulmonary fibrosis that, in the opinion of the Investigator, requires treatment with approved therapies * Prebronchodilator forced expiratory volume in 1 second (FEV1)/FVC \<0.7 at Visit 1b * HRCT findings consistent with probable or definite usual interstitial pneumonia (UIP) pattern * Any medical condition that is known to predispose to the development of pulmonary fibrosis (e.g. known connective tissue disease) * Prior or current use of nerandomilast, nintedanib, or pirfenidone Further exclusion criteria apply.

Conditions

Familial Pulmonary Fibrosis Interstitial Lung Abnormalities Interstitial Lung Diseases

Locations

  • University of California Los Angeles — Los Angeles, California, United States
  • University of Colorado Denver — Aurora, Colorado, United States
  • Clinical Research Specialists LLC - Kissimmee — Kissimmee, Florida, United States
  • University of Kansas Medical Center — Kansas City, Kansas, United States
  • Brigham and Women's Hospital — Boston, Massachusetts, United States
  • University of Michigan — Ann Arbor, Michigan, United States
  • University of Minnesota — Minneapolis, Minnesota, United States
  • Weill Cornell Medicine-New York-60569 — New York, New York, United States
  • University of Pennsylvania — Philadelphia, Pennsylvania, United States
  • Medical University of South Carolina — Charleston, South Carolina, United States
  • Vanderbilt University Medical Center — Nashville, Tennessee, United States
  • Baylor College of Medicine — Houston, Texas, United States
  • Virginia Commonwealth University — Richmond, Virginia, United States
  • Centro de Investigaciones Metabolicas (CINME) — Buenos Aires, Argentina
  • Hospital Italiano de Buenos Aires — CABA, Argentina
  • Fundacion NIBA Neurologia Infantil Buenos Aires — CABA, Argentina
  • Centro de Investigacion Clinica Belgrano — CABA, Argentina
  • Consultorios Medicos del Buen Ayre — Capital Federal, Argentina
  • Royal Prince Alfred Hospital — Camperdown, New South Wales, Australia
  • Lung Research Queensland — Chermside, Queensland, Australia
  • The Prince Charles Hospital — Chermside, Queensland, Australia
  • The Alfred Hospital — Melbourne, Victoria, Australia
  • Cliniques Universitaires Saint-Luc — Brussels, Belgium
  • UZ Leuven — Leuven, Belgium
  • St. Joseph's Healthcare Hamilton — Hamilton, Ontario, Canada
  • McGill University Health Centre (MUHC) — Montreal, Quebec, Canada
  • Hopital Louis Pradel — Bron, France
  • INS Coeur Poumon — Lille, France
  • HOP Bichat — Paris, France
  • HOP Pontchaillou — Rennes, France
  • Hôpital Larrey - CHU de Toulouse — Toulouse, France
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH — Essen, Germany
  • Medizinische Hochschule Hannover — Hanover, Germany
  • Lungenfachklinik Immenhausen — Immenhausen, Germany
  • Krankenhaus Bethanien gGmbH — Solingen, Germany
  • IRCCS MultiMedica — Milan, Italy
  • Azienda Ospedaliera Universitaria di Padova — Padova, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma, Italy
  • Tosei General Hospital — Aichi, Seto, Japan
  • Tsuboi Hospital — Fukushima, Koriyama, Japan
  • Kanagawa Cardiovascular and Respiratory Center — Kanagawa, Yokohama, Japan
  • National Hospital Organization Kinki-Chuo Chest Medical Center — Osaka, Sakai, Japan
  • Hamamatsu University Hospital — Shizuoka, Hamamatsu, Japan
  • National Center for Global Health and Medicine — Tokyo, Shinjuku-ku, Japan
  • St. Antonius Ziekenhuis — Nieuwegein, Netherlands
  • Erasmus Medisch Centrum — Rotterdam, Netherlands
  • Severance Hospital — Seoul, South Korea
  • Asan Medical Center — Seoul, South Korea
  • Samsung Medical Center — Seoul, South Korea
  • Hospital de Galdakao — Galdakao, Spain
  • Hospital Universitari de Bellvitge — L'Hospitalet Del Llobregat, Spain
  • Hospital Universitario De La Princesa — Madrid, Spain
  • Hospital Virgen del Rocio — Seville, Spain
  • Royal Devon and Exeter Hospital, Wonford — Exeter, United Kingdom
  • Royal Brompton Hospital — London, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record